Work

Supplementary Figure S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

Year: 2025

Type: supplementary-materials

Abstract: Figure S6 shows the FDA meta-analysis results for the overall survival endpoint across the three randomized studies (E1910, 20120215, AALL1331) and the literature study.

DOI: 10.1158/1078-0432.30363072

Authors: Cara A. Rabik, Shu Wang, Ritu Chadda, Donna Przepiorka, Jonathon Vallejo, Xiling Jiang, Marc R. Theoret, R. Angelo de Claro

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4415241040

Cites:

Cited by:

Related to: